empa-reg-outcome-recurrent-events

Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME ® trialIn new results published in The Lancet Diabetes& Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular diseaseRecurrent cardiovascular events in people with type 2 diabetes are responsible for considerable clinical and socioeconomic burdens;1  evaluation of first and recurrent events allows estimation of the total burden of cardiovascular events
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news